Therapeutic approaches in patients with newly diagnosed follicular lymphoma.
The prognosis of follicular lymphoma (FL) has significantly improved over the last decade, particularly following the introduction of the anti-CD20 monoclonal antibody rituximab, which has challenged the old concept of FL as an incurable disease. However, the decision whether to start treatment in a patient with advanced FL or adopt a watch-and-wait policy remains a subject of controversy. Furthermore, the optimal first-line treatment for FL remains a clinical challenge owing to the numerous different therapeutic options available. In this review, the authors focus on the initial management of patients with newly diagnosed FL, consider the different treatment options for every stage, paying special consideration to the therapeutic approaches for each clinical scenario, and discuss future directions.
Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C/Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain.
David
D
Aguiar-Bujanda
María Jesús
MJ
Blanco-Sánchez
Pedro
P
Jiménez-Gallego
Marta
M
Mori-De Santiago
María
M
Hernández-Sosa
Saray
S
Galván-Ruíz
Samuel
S
Hernández-Sarmiento
Salvador
S
Saura-Grau
Uriel
U
Bohn-Sarmiento
D002986:Clinical Trials as Topic; D006801:Humans; D008224:Lymphoma, Follicular / Q000628:therapy*
chemotherapy; consolidation; first-line treatment; follicular lymphoma; immunochemotherapy; maintenance; radioimmunotherapy; review; rituximab